Alzamend Neuro Inc (ALZN)

Healthcare | Biotechnology
Income Statement (Quarterly) 2025-07-31 2025-01-31 2024-10-31 2024-07-31
Revenue 0 0 0 0
Cost of Revenue 0 12,685 12,685 12,685
Gross Profit 0 0 0 -12,685
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 959,334 590,304 1,047,000 755,834
Operating Expenses 2,700,201 1,037,000 1,358,000 962,405
Operating Income -2,700,201 -1,037,000 -1,358,000 -962,000
Interest Expense -2,483 2,019 3,495 12,006
Income Before Tax -2,702,684 -1,039,000 -1,362,000 -974,000
Income Tax Expense 0 0 0 0
Net Income -2,702,684 -1,039,000 -1,362,000 -974,000
Per Share
EPS -1.28 -0.19 -0.40 -1.25
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Revenue 0 0 0 0 0
Cost of Revenue 50,740 0 0 0 0
Gross Profit -50,740 -50,740 -23,066 0 0
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 3,031,156 3,483,000 7,425,000 7,118,221 3,641,172
Operating Expenses 4,446,084 9,938,000 14,870,000 12,319,535 4,951,888
Operating Income -4,496,824 -9,938,000 -14,870,000 -12,319,535 -4,951,888
Interest Expense 18,029 10,101 7,701 46,524 158,803
Income Before Tax -4,514,853 -9,948,000 -14,878,000 -12,362,059 -5,046,567
Income Tax Expense 0 0 -145,000 42,524 0
Net Income -4,514,853 -9,948,000 -14,878,000 -12,404,583 -5,046,567
Per Share
EPS -11.32 -14.72 -2.25 -2.09 -0.06
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Assets
Cash and Cash Equivalents 376,048 5,140,859 14,063,811 1,929,270
Short Term Investments 0 0 0 0
Net Receivables 0 0 0 16,210
Inventory 0 0 0 0
Total Current Assets 455,242 5,835,782 14,413,534 2,912,590
Property Plant Equipment 176,346 79,843 102,909 0
Goodwill and Intangibles 0 0 0 0
Total Assets 631,588 5,915,625 14,516,443 2,912,590
Liabilities
Account Payables 2,925,059 2,870,122 1,162,850 503,591
Short Term Debt 300,714 0 0 335,303
Total Current Liabilities 3,225,773 2,870,122 1,164,932 899,643
Long Term Debt 0 0 0 0
Total Liabilities 3,225,773 2,870,122 1,164,932 899,643
Shareholders Equity
Retained Earnings -54,020,408 -44,072,662 -29,194,495 -16,832,436
Total Shareholders Equity -2,594,185 3,045,503 13,351,511 2,012,947
Balance Sheet (Annual) 2024-04-30 2023-04-30 2022-04-30 2021-04-30 2020-04-30
Assets
Cash and Cash Equivalents 376,048 5,140,859 14,063,811 1,929,270 90,285
Short Term Investments 0 0 0 0 0
Net Receivables 0 0 0 16,210 194,278
Inventory 0 0 0 0 0
Total Current Assets 455,242 5,835,782 14,413,534 2,912,590 1,814,015
Property Plant Equipment 176,346 79,843 102,909 0 0
Goodwill and Intangibles 0 0 0 0 0
Total Assets 631,588 5,915,625 14,516,443 2,912,590 1,814,015
Liabilities
Account Payables 2,925,059 2,870,122 1,162,850 503,591 929,639
Short Term Debt 300,714 0 0 335,303 0
Total Current Liabilities 3,225,773 2,870,122 1,164,932 899,643 992,306
Long Term Debt 0 0 0 0 0
Total Liabilities 3,225,773 2,870,122 1,164,932 899,643 992,306
Shareholders Equity
Retained Earnings -54,020,408 -44,072,662 -29,194,495 -16,832,436 -11,785,869
Total Shareholders Equity -2,594,185 3,045,503 13,351,511 2,012,947 821,709
Cash Flow Statement (Quarterly) 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Operating Activities
Net Income -4,514,853 -9,947,746 -14,878,167 -12,362,059
Depreciation & Amortization 50,740 50,740 23,066 3,549
Stock Based Compensation 325,108 955,633 3,582,625 4,408,569
Change in Working Capital -2,438,467 670,666 2,349,324 1,327,181
Operating Cash Flow -6,568,186 -8,269,993 -8,923,152 -6,613,990
Investing Activities
Capital Expenditure -300,000 -147,243 0 -106,458
Investments -300,000 -147,243 0 -106,458
Investing Cash Flow -300,000 -147,243 0 -106,458
Financing Activities
Debt Repayment 0 300,000 0 -58,667
Common Stock Issued/Repurchased 2,704,052 1,252,425 989,334 18,911,456
Dividends Paid 0 0 0 0
Financing Cash Flow 10,440,796 3,652,425 200 18,854,989
Summary
Free Cash Flow -6,868,186 -8,417,236 -8,923,152 -6,720,448
Net Change in Cash 3,572,610 -4,764,811 -8,922,952 12,134,541
Cash Flow Statement (Annual) 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Operating Activities
Net Income -4,514,853 -9,947,746 -14,878,167 -12,362,059 -5,046,567
Depreciation & Amortization 50,740 50,740 23,066 3,549 0
Stock Based Compensation 325,108 955,633 3,582,625 4,408,569 2,032,359
Change in Working Capital -2,438,467 670,666 2,349,324 1,327,181 -152,451
Operating Cash Flow -6,568,186 -8,269,993 -8,923,152 -6,613,990 -2,712,027
Investing Activities
Capital Expenditure -300,000 -147,243 0 -106,458 0
Investments -300,000 -147,243 0 -106,458 0
Investing Cash Flow -300,000 -147,243 0 -106,458 100,915
Financing Activities
Debt Repayment 0 300,000 0 -58,667 -1,918
Common Stock Issued/Repurchased 2,704,052 1,252,425 989,334 18,911,456 2,100,000
Dividends Paid 0 0 0 0 0
Financing Cash Flow 10,440,796 3,652,425 200 18,854,989 4,450,097
Summary
Free Cash Flow -6,868,186 -8,417,236 -8,923,152 -6,720,448 -2,712,027
Net Change in Cash 3,572,610 -4,764,811 -8,922,952 12,134,541 1,838,985